Author:
Ma Yuxiang,Luo Fan,Zhang Yang,Liu Qianwen,Xue Jinhui,Huang Yan,Zhao Yuanyuan,Yang Yunpeng,Fang Wenfeng,Zhou Ting,Chen Gang,Cao Jiaxin,Chen Qun,She Xiaohong,Luo Peter,Liu Guizhong,Zhang Li,Zhao Hongyun
Funder
National Postdoctoral Program for Innovative Talents
China Postdoctoral Science Foundation
National Natural Science Foundation of China
Guangxi Key Research and Development Program
Reference42 articles.
1. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?;Shin;Curr. Opin. Immunol.,2015
2. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy;Moran;Curr. Opin. Immunol.,2013
3. Immuno-oncology combinations: a review of clinical experience and future prospects;Antonia;Clin. Cancer Res.,2014
4. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer;Segal;Clin. Cancer Res.,2018
5. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer;Lynch;Immunol. Rev.,2008